Theriva Biologics, Inc.

NYSEAM:TOVX Stock Report

Market Cap: US$3.4m

Theriva Biologics Valuation

Is TOVX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of TOVX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate TOVX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate TOVX's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for TOVX?

Key metric: As TOVX is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for TOVX. This is calculated by dividing TOVX's market cap by their current book value.
What is TOVX's PB Ratio?
PB Ratio0.1x
BookUS$24.64m
Market CapUS$3.40m

Price to Book Ratio vs Peers

How does TOVX's PB Ratio compare to its peers?

The above table shows the PB ratio for TOVX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average0.8x
OGEN Oragenics
2.5xn/aUS$3.7m
ONCR Oncorus
0.1xn/aUS$3.3m
ONCT Oncternal Therapeutics
0.2x-29.5%US$2.1m
PALI Palisade Bio
0.5x-36.4%US$3.2m
TOVX Theriva Biologics
0.1x-8.9%US$3.4m

Price-To-Book vs Peers: TOVX is good value based on its Price-To-Book Ratio (0.1x) compared to the peer average (0.8x).

Price to Book Ratio vs Industry

How does TOVX's PB Ratio compare vs other companies in the US Biotechs Industry?

59 CompaniesPrice / BookEstimated GrowthMarket Cap
Industry Avg.1.9x28.3%
TOVX Theriva Biologics
 0.1x-8.9%US$3.40m
GRAL GRAIL
0.2x35.7%US$594.06m
AMRN Amarin
0.4x-7.7%US$217.60m
TOVX 0.1xIndustry Avg. 1.9xNo. of Companies78PB01.63.24.86.48+
59 CompaniesEstimated GrowthMarket Cap
Industry Avg.1.9x28.3%
TOVX Theriva Biologics
 0.1x-8.9%US$3.40m
No more companies

Price-To-Book vs Industry: TOVX is good value based on its Price-To-Book Ratio (0.1x) compared to the US Biotechs industry average (1.9x).

Price to Book Ratio vs Fair Ratio

What is TOVX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TOVX PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio0.1x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate TOVX's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst TOVX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$1.28
US$90.50
+6,970.3%
93.4%US$175.00US$6.00n/a2
Nov ’25US$1.99
US$100.00
+4,925.1%
75.0%US$175.00US$25.00n/a2
Oct ’25US$1.28
US$100.00
+7,712.5%
75.0%US$175.00US$25.00n/a2
Sep ’25US$5.90
US$100.00
+1,594.9%
75.0%US$175.00US$25.00n/a2
May ’25US$10.15
US$112.50
+1,008.2%
55.6%US$175.00US$50.00n/a2
Apr ’25US$11.09
US$112.50
+914.9%
55.6%US$175.00US$50.00n/a2
Mar ’25US$12.37
US$112.50
+809.5%
55.6%US$175.00US$50.00n/a2
Feb ’25US$12.89
US$112.50
+772.8%
55.6%US$175.00US$50.00n/a2
Jan ’25US$10.75
US$112.50
+946.3%
55.6%US$175.00US$50.00n/a2
Dec ’24US$15.00
US$112.50
+650.0%
55.6%US$175.00US$50.00n/a2
Nov ’24US$11.13
US$112.50
+911.2%
55.6%US$175.00US$50.00US$1.992
Oct ’24US$13.48
US$112.50
+734.4%
55.6%US$175.00US$50.00US$1.282
Sep ’24US$12.87
US$112.50
+774.0%
55.6%US$175.00US$50.00US$5.902
Aug ’24US$16.25
US$137.50
+746.0%
27.3%US$175.00US$100.00US$5.462
Jul ’24US$25.00
US$137.50
+450.0%
27.3%US$175.00US$100.00US$6.032
Jun ’24US$15.98
US$137.50
+760.6%
27.3%US$175.00US$100.00US$6.252
May ’24US$15.98
US$137.50
+760.5%
27.3%US$175.00US$100.00US$10.152
Apr ’24US$17.46
US$137.50
+687.5%
27.3%US$175.00US$100.00US$11.092
Mar ’24US$21.62
US$137.50
+535.9%
27.3%US$175.00US$100.00US$12.372
Feb ’24US$23.25
US$137.50
+491.4%
27.3%US$175.00US$100.00US$12.892
Jan ’24US$11.37
US$137.50
+1,109.3%
27.3%US$175.00US$100.00US$10.752
Dec ’23US$18.00
US$137.50
+663.9%
27.3%US$175.00US$100.00US$15.002
Nov ’23US$19.40
US$137.50
+608.8%
27.3%US$175.00US$100.00US$11.132

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$57.86

7D

3.9%

1Y

15.0%

Teva Pharmaceutical Industries

US$18.9b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEVA

US$16.59

7D

-1.3%

1Y

69.3%

Collegium Pharmaceutical

US$993.0m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$31.19

7D

4.8%

1Y

22.3%